The primary goal of the X-ray Crystallography Core is to enable and facilitate the research of MSKCClaboratories that use X-ray crystallography as a tool to address questions in their research programs. Thefacility maintains in-house equipment for data collection, processing and structure determination, implementsa wide range of crystallographic and structure analysis software packages, provides long-term regularaccess to state-of-the-art synchrotron beamlines through participation in multi-institutional consortia at twonational laboratory locations, provides training and technical assistance to users of both the in-house andremote facilities, and provides expertise in structural biology and modeling and guidance to non-structuralMSKCC laboratories that benefit from the use of available structures in the design and interpretation ofexperiments.Structural biology has been playing an increasing role in understanding the many biological processesimportant in cancer and in accelerating the pace of anti-cancer drug discovery. In the post-genomic era, theneed for structural data to understand biological function and regulation, to provide scaffolds for the designor improvement of candidate anticancer compounds, and to help identify molecular function will increase withthe application of massively parallel data acquisition tools such as DMA arrays, global protein-proteininteraction maps and large scale identification of cancer-related genes. This will require increasedthroughput from conventional X-ray crystallography facilities, and new, state-of-the-art synchrotron facilitiesto accelerate structure determination and to allow the study of increasingly large and complex structures andmacromolecular assemblies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA008748-43
Application #
7671825
Study Section
Subcommittee G - Education (NCI)
Project Start
2008-07-31
Project End
2012-12-31
Budget Start
2008-07-31
Budget End
2008-12-31
Support Year
43
Fiscal Year
2008
Total Cost
$157,458
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Moo, Tracy-Ann; Edelweiss, Marcia; Hajiyeva, Sabina et al. (2018) Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection? Ann Surg Oncol 25:1488-1494
Kinsley, Karen; Pritchett, Wendy (2018) Liposomal Irinotecan: Nursing Considerations in an Outpatient Cancer Center Clin J Oncol Nurs 22:221-224
Vargas, Hebert Alberto; Kramer, Gem M; Scott, Andrew M et al. (2018) Reproducibility and Repeatability of Semiquantitative 18F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study. J Nucl Med 59:1516-1523
Ho, A L (2018) Developing androgen receptor targeting for salivary gland cancers. Ann Oncol 29:792-794
Gupta, Piyush; Migliacci, Jocelyn C; Hay, Ashley et al. (2018) Validation and assessment of discordance of the 8th edition AJCC (American Joint Committee on Cancer) clinical and pathologic staging systems in patients with p16+ oropharyngeal cancer treated with surgery and adjuvant radiation at a single institution. Oral Oncol 83:140-146
Aras, Omer; Pearce, Gillian; Watkins, Adam J et al. (2018) An in-vivo pilot study into the effects of FDG-mNP in cancer in mice. PLoS One 13:e0202482
Chou, Chun; Li, Ming O (2018) Tissue-Resident Lymphocytes Across Innate and Adaptive Lineages. Front Immunol 9:2104
Quezada-Diaz, Felipe; Jimenez-Rodriguez, Rosa M; Pappou, Emmanouil P et al. (2018) Effect of Neoadjuvant Systemic Chemotherapy With or Without Chemoradiation on Bowel Function in Rectal Cancer Patients Treated With Total Mesorectal Excision. J Gastrointest Surg :
Schleicher, Stephen M; Bach, Peter B; Matsoukas, Konstantina et al. (2018) Medication overuse in oncology: current trends and future implications for patients and society. Lancet Oncol 19:e200-e208
Moore, Amanda R; Ran, Leili; Guan, Youxin et al. (2018) GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma. Cell Rep 22:2455-2468

Showing the most recent 10 out of 8799 publications